ArticleEuropean journal of histochemistry : EJH2026
SUSD2 suppresses lung adenocarcinoma tumorigenesis by inducing autophagy
Article in European journal of histochemistry : EJH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LUAD) is the most common and aggressive non-small cell lung cancer with limited therapeutic options. SUSD2 exhibits varying regulatory behaviors in different types of tumors, its role in LUAD remains unclear. This study aims to determine the role of SUSD2 in LUAD and explore the underlying mechanism. Through TCGA database analysis, we discovered that SUSD2 expression is significantly downregulated in LUAD tissues, and its low expression is closely associated with advanced disease stages and poor patient prognosis. Further immunohistochemical validation confirmed reduced SUSD2 expression in clinical samples. Functional assays demonstrated that SUSD2 overexpression markedly inhibits LUAD cell proliferation, migration, and invasion, and also suppresses tumor growth and metastasis in mouse models. Mechanistic studies revealed that SUSD2 overexpression promotes autophagic flux (indicated by increased LC3-II and decreased p62) and suppresses the PI3K/AKT/mTOR signaling pathway. The antitumor effects of SUSD2 were attenuated by the autophagy inhibitor 3-MA or ATG5 knockdown, while reactivation of mTOR reversed SUSD2-induced autophagy and tumor suppression. In summary, SUSD2 functions as a tumor suppressor in LUAD by inducing autophagy and inhibiting the PI3K/AKT/mTOR pathway, suggesting its potential as a therapeutic target and prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.